Trial Profile
A Phase 2 Open-Label Study of the CSF-1R Inhibitor JNJ-40346527 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Edicotinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 13 Nov 2020 Status changed from active, no longer recruiting to discontinued as not enough enrollment to determine efficacy.
- 24 Jun 2020 Planned number of patients changed from 100 to 28.
- 24 Jun 2020 Status changed from recruiting to active, no longer recruiting.